Featured Research

from universities, journals, and other organizations

New Therapy For HIV Treatment

Date:
July 30, 2008
Source:
University of New South Wales
Summary:
Millions of people world-wide who have contracted a highly resistant strain of the HIV virus could benefit from a new drug to treat the infection.

Millions of people world-wide who have contracted a highly resistant strain of HIV could benefit from a new drug to treat the infection, according to UNSW research.

Co-authored by UNSW's National Centre in HIV Epidemiology and Clinical Research (NCHECR), the research shows that the majority of patients who have not responded to traditional treatments have had good results from a new combination therapy involving raltegravir.

Raltegravir is already available in Australia and was listed on the Pharmaceutical Benefits Scheme on July 1st, with clinical trials showing that it is safe, effective and with minimal side-effects when used with other anti-HIV medicines.

The study, which has been published in the New England Journal of Medicine, shows raltegravir lowers the amount of virus in the blood to undetectable levels in 62 percent of people taking it in combination with other anti-HIV medicines.

Only one in three people who received a placebo plus other anti-HIV medicines had the amount of virus in the blood reduced to similar levels.

“This is the first drug in a new class of antiretroviral drugs called integrase inhibitors,” says UNSW Professor David Cooper AO, the Director of NCHECR. “The drug has a different mechanism of action, is very potent, seems very safe and has helped patients who have a virus that is resistant to older drugs and classes.

“It initially will be used in developed countries, but hopefully it will be made available at cheaper prices for patients in developing countries who are facing the same problems,” Professor Cooper says.

The results were based on analyses of viral load reductions and CD4 cell count increases. A high CD4 cell count is crucial for a healthy immune system.

The overall results have been drawn from two major ongoing clinical trials in Europe, Asia, Australia and North and South America. Both studies are supported by Merck & Co, Inc., the manufacturer of raltegravir.

Professor Cooper is the first author of the second of two papers published in this edition of the New England Journal of Medicine. The first is led by Professor Roy Steigbigel from Stony Brook University Medical Center.


Story Source:

The above story is based on materials provided by University of New South Wales. Note: Materials may be edited for content and length.


Cite This Page:

University of New South Wales. "New Therapy For HIV Treatment." ScienceDaily. ScienceDaily, 30 July 2008. <www.sciencedaily.com/releases/2008/07/080729133622.htm>.
University of New South Wales. (2008, July 30). New Therapy For HIV Treatment. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2008/07/080729133622.htm
University of New South Wales. "New Therapy For HIV Treatment." ScienceDaily. www.sciencedaily.com/releases/2008/07/080729133622.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Robotic Hair Restoration

Robotic Hair Restoration

Ivanhoe (Oct. 1, 2014) A new robotic procedure is changing the way we transplant hair. The ARTAS robot leaves no linear scarring and provides more natural results. Video provided by Ivanhoe
Powered by NewsLook.com
Insertable Cardiac Monitor

Insertable Cardiac Monitor

Ivanhoe (Oct. 1, 2014) A heart monitor the size of a paperclip that can save your life. The “Reveal Linq” allows a doctor to monitor patients with A-Fib on a continuous basis for up to 3 years! Video provided by Ivanhoe
Powered by NewsLook.com
Attacking Superbugs

Attacking Superbugs

Ivanhoe (Oct. 1, 2014) Two weapons hospitals can use to attack superbugs. Scientists in Ireland created a new gel resistant to superbugs, and a robot that can disinfect a room in minutes. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins